Union Minister of State (Independent Charge) for Science and Technology Dr. Jitendra Singh on Tuesday, June 16, 2026, highlighted a reported nineteen-fold expansion in India's bioeconomy — from $10 billion to $190 billion over 12 years — framing the milestone as a signature achievement of the Modi government under the hashtag #12YearsOfSeva.

Context

The minister's post cited a report noting that India's bioeconomy has grown from approximately $10 billion to $190 billion in the twelve years since 2014, when the Narendra Modi-led government assumed office. The claim is being amplified as part of a broader government communication drive marking 12 years of the current administration's tenure. Dr. Singh, who has held charge of the Department of Biotechnology (DBT) since 2014, has been a consistent advocate for positioning life sciences as a pillar of India's economic growth story.

Policy Backdrop

The reported growth trajectory tracks closely with a series of policy interventions rolled out since 2014. The National Biotechnology Development Strategy (2015–2020) set explicit targets for expanding the sector through increased public R&D investment, startup incubation and export promotion. The Biotechnology Industry Research Assistance Council (BIRAC), established in 2012 and subsequently scaled under DBT, has served as the primary funding bridge between academic research and commercial biotechnology ventures.

Successive rounds of BIRAC grants have supported areas ranging from vaccine manufacturing — brought into sharp focus during the COVID-19 pandemic — to agricultural biotechnology and bio-pharma exports. The sector's expansion also aligns with the government's Atmanirbhar Bharat framework, which identified life sciences as a strategic domain for self-reliance and global competitiveness.

Stakeholders and Impact

The beneficiaries of this reported expansion span a wide ecosystem: biotech startups that have accessed BIRAC seed and scale-up funding, pharmaceutical firms that have deepened their biologics pipelines, and research institutions that have partnered with industry under DBT-facilitated programmes. India's growing share in global generic biologics and biosimilar exports is frequently cited as evidence of the sector's commercial maturation.

For domestic consumers and public health planners, an expanded bioeconomy has implications for vaccine availability, affordable diagnostics and agricultural productivity — areas where biotechnology intersects directly with food and health security.

What's Next

Attention will now turn to the release of the next National Biotechnology Development Strategy document, which is expected to set fresh targets for the sector beyond the current planning horizon. Bioeconomy-specific allocations in the forthcoming Union Budget will be closely watched by industry stakeholders as an indicator of whether the government intends to sustain this growth pace into the next decade. If the reported $190 billion valuation is formally validated and institutionalised as a baseline, it could anchor India's pitch to global investors as a preferred destination for life-sciences capital.